Other grades of this product :
| Disopyramid phosphate Basic information |
| Product Name: | Disopyramid phosphate | | Synonyms: | DISOPYRAMIDE PHOSPHATE;DISOPYRAMIDE PHOSPHATE SALT;disopyramid phosphate;ALPHA-DIISOPROPYLAMINOETHYL-ALPHA-PHENYLPYRIDINE-2-ACET-AMIDE PHOSPHATE SALT;RYTHMODAN;norpace cr;2-[1-(ammoniocarbonyl)-3-(diisopropylammonio)-1-phenylpropyl)]pyridinium phosphate;4-(diisopropylaMino)-2-phenyl-2-(pyridin-2-yl)butanaMide phosphate | | CAS: | 22059-60-5 | | MF: | C21H32N3O5P | | MW: | 437.47 | | EINECS: | 244-756-1 | | Product Categories: | | Mol File: | 22059-60-5.mol |
| Disopyramid phosphate Chemical Properties |
| Melting point | 202-204°C | | storage temp. | 2-8°C | | solubility | DMSO (Slightly, Heated, Sonicated), Methanol (Slightly), Water (Slightly) | | form | neat | | color | White to Off-White |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 36 | | WGK Germany | 3 | | RTECS | UR8440000 | | HS Code | 2933399090 |
| Disopyramid phosphate Usage And Synthesis |
| Originator | Rythmodan,Cassenne,France,1969 | | Uses | Disopyramide Phosphate is an antiarrhythmic (class IA). Sodium channel blocker. | | Uses | Disopyramide phosphate salt has been used as an internal standard for plasma sample analysis by mass spectrometry. It might be used as a test compound in a teratogenicity study. | | Uses | Cardiac depressant (anti-arrhythmic). | | Manufacturing Process | To a solution of 35.3 parts of phenylacetonitrile and 47.6 parts of 2-
bromopyridine in 175 parts of dry toluene is added 53.4 parts of sodamide
slowly with stirring over a period of 45 minutes. The resultant mixture is
stirred at 100°C for 2 hours before it is cooled and the excess sodamide is
decomposed by the addition of water. The toluene layer is separated and
washed with water to remove excess alkali. The toluene solution is extracted
with 6 N hydrochloric acid and the acid extract is made alkaline and then
extracted with toluene. The toluene solution is dried over sodium sulfate and
the solvent is evaporated. Recrystallization of the residue from alcohol-hexane
gives α-phenyl-2-pyridineacetonitrile melting at about 87-88°C.To a solution of 41 parts of α-phenyl-2-pyridineacetonitrile in 350 parts of dry
toluene is added 9.2 parts of sodamide and the mixture is stirred and heated
at 90°C for 30 minutes. Heating is stopped and a solution of 38.5 parts of 2-
diisopropylaminoethyl chloride in 110 parts of dry toluene is added slowly over
a period of 30 minutes. The mixture is stirred and refluxed for 6 hours before
it is cooled and decomposed by the addition of water. The toluene layer is
separated and washed with water and extracted with 6 N hydrochloric acid.
The acid extract is made alkaline and extracted with toluene. The toluene
solution is washed with water and dried and the solvent is evaporated.
Distillation of the residue gives 4-diisopropylamino-2-phenyl-2-(2-pyridyl)-
butyronitrile boiling at about 145°-160°C at 0.3 mm pressure.A solution of 27.2 parts of 4-diisopropylamino-2-phenyl-2-(2-
pyridyl)butyronitrile in 200 parts of concentrated sulfuric acid is heated on a
steam bath for 4 hours and then poured onto ice. The resultant mixture is
alkalized with 10 N sodium hydroxide, and the pH is adjusted to 6 by the
addition of acetic acid. The solution is washed once with benzene before it is
alkalized again with 10 N sodium hydroxide solution. The resultant mixture is
extracted with benzene, and the solvent is evaporated from the benzene
extract. The resultant residue is dissolved in ethanol and the alcohol solution
is treated with charcoal and filtered. Evaporation of the solvent leaves a
residue which is recrystallized from hexane to give 4-diisopropylamino-2-
phenyl-2-(2-pyridyl)butyramide melting at about 94.5-95°C. It may be
converted to the phosphate with phosphoric acid. | | Brand name | Norpace (Searle). | | Therapeutic Function | Antiarrhythmic | | General Description | Disopyramide phosphate, -[2(diisopropylamino)ethyl]- -phenyl-2-pyridineacetamidephosphate (Norpace), is an oral and intravenousclass IA antiarrhythmic agent. It is quite similar to quinidineand procainamide in its electrophysiological properties, inthat it decreases phase 4 diastolic depolarization, decreasesconduction velocity, and has vagolytic properties.31 It is usedclinically in the treatment of refractory, life-threatening ventriculartachyarrhythmias. Oral administration of the drugproduces peak plasma levels within 2 hours. The drug isbound approximately 50% to plasma protein and has a halflifeof 6.7 hours in humans. More than 50% is excretedunchanged in the urine. Therefore, patients with renal insufficiencyshould be monitored carefully for evidence ofoverdose. Disopyramide phosphate commonly exhibits sideeffects of dry mouth, constipation, urinary retention, andother cholinergic blocking actions because of its structuralsimilarity to anticholinergic drugs. | | Biochem/physiol Actions | Class IA antiarrhythmic; sodium channel blocker |
| Disopyramid phosphate Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye